CytoDyn (CYDY) Return on Capital Employed (2011 - 2026)
CytoDyn (CYDY) posted Return on Capital Employed of 103.51% for Q1 2026, up 114.27% on a QoQ basis from 48.31% in Q4 2025, and up 12054.0% year-over-year from N/an in Q1 2025.
CytoDyn (CYDY) Return on Capital Employed (2011 - 2026) Analysis & Trends
CytoDyn's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 103.51% for Q1 2026.
- Quarterly Return on Capital Employed rose 12054.0% year-over-year to 103.51% in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 103.51% (up 12054.0% YoY) and the FY2025 annual result came in at 17.27%, down 4202.0% from the prior year.
- Return on Capital Employed was 103.51% for Q1 2026 at CytoDyn, up from 48.31% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 523.3% in Q1 2022 and bottomed at 19.65% in Q4 2024.
- A 5-year average of 80.18% and a median of 33.03% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 7050611 bps — and 2026, when it surged 12054 bps.
- CytoDyn's Return on Capital Employed stood at 125.12% in 2022, then plunged by 89 bps to 13.95% in 2023, then sank by 241 bps to 19.65% in 2024, then soared by 346 bps to 48.31% in 2025, then soared by 114 bps to 103.51% in 2026.
- Business Quant data shows CYDY's Return on Capital Employed at 103.51% in Q1 2026, 48.31% in Q4 2025, and 33.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | 103.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 103.51% |
| Nov 30, 2025 | 48.31% |
| Aug 31, 2025 | 33.03% |
| May 31, 2025 | -18.98% |
| Feb 28, 2025 | -17.03% |
| Nov 30, 2024 | -19.65% |
| Aug 31, 2024 | -17.99% |
| May 31, 2024 | 24.58% |
| Feb 29, 2024 | 12.70% |
| Nov 30, 2023 | 13.95% |
| Aug 31, 2023 | 30.27% |
| May 31, 2023 | 37.98% |
| Feb 28, 2023 | 104.86% |
| Nov 30, 2022 | 125.12% |
| Aug 31, 2022 | 142.71% |
| May 31, 2022 | 236.32% |
| Feb 28, 2022 | 523.30% |
| Nov 30, 2021 | 875.89% |
| Aug 31, 2021 | 904.41% |
| May 31, 2021 | 352.07% |